Pathology & Oncology Research最新文献

{"title":"Diagnostic and prognostic significance of keloid-like collagen remodeling patterns in the extracellular matrix of colorectal cancer.","authors":"Nauryzbay M Imanbayev, Yerbolat M Iztleuov, Yevgeniy K Kamyshanskiy, Aigul V Zhumasheva","doi":"10.3389/pore.2024.1611789","DOIUrl":"10.3389/pore.2024.1611789","url":null,"abstract":"<p><strong>Background: </strong>The desmoplastic reaction is considered a promising prognostic parameter for colorectal cancer. However, intermediate desmoplastic reaction is characterized by sizeable stromal heterogeneity, including both small amounts of keloid-like collagen (KC) in the fibrotic stroma and thick tufts of KC circumferentially surrounding cancer nests and occupying most of the fields of view. The present study aimed to evaluate the diagnostic and prognostic significance of KC histophenotyping with a quantitative visual assessment of its presence in the stroma of the invasive margin of TNM (The \"tumor-node-metastasis\" classification) stage II/III colorectal cancer (CRC).</p><p><strong>Methods and results: </strong>175 resected tumors from patients with TNM stage II/III CRC were examined. Keloid-like collagen was assessed according to Ueno H. criteria. KC was assessed at the primary tumor invasive margin using Hematoxylin & Eosin and Masson's trichrome staining. The cut-off point for KC was examined using \"the best cutoff approach by log-rank test.\" Using a cutoff point of 30%, we histologically divided fibrous stroma in the invasive area into two groups: \"type A\"-KC ≤ 0.3 and \"type B\"-KC>0.3. Type A stroma was observed in 48% of patients, type B-in 52%. The association between collagen amount and 5-year recurrence-free survival (5-RFS) was assessed using Cox regression analysis. Kaplan-Meier analysis and log-rank tests were used to assess the significance of survival analysis. Analysis of categorical variables showed that increased KC in CRC stroma predicted adverse outcomes for 5-RFS (hazard ratio [HR] = 3.143, 95%, confidence interval [CI] = 1.643-6.012, <i>p</i> = 0.001). Moreover, in Kaplan-Meier analysis, the log-rank test showed that type B exhibited worse 5-RFS than type A (<i>p</i> = 0.000).</p><p><strong>Conclusion: </strong>KC is an independent predictor of 5-year overall and RFS in patients with TNM stage II/III CRC treated with surgery, with worse survival rates when the amount of KC increases by >30%.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611789"},"PeriodicalIF":2.3,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11186984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141432551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric epithelial neoplasm of fundic-gland mucosa lineage: representative of the low atypia differentiated gastric tumor and Ki67 may help in their identification.","authors":"Houqiang Li, Lanqing Zheng, Guodong Zhong, Xunbin Yu, Xia Zhang, Linying Chen, Xin Chen","doi":"10.3389/pore.2024.1611734","DOIUrl":"10.3389/pore.2024.1611734","url":null,"abstract":"<p><strong>Background: </strong>Gastric epithelial neoplasm of the fundic-gland mucosa lineages (GEN-FGMLs) are rare forms of gastric tumors that encompass oxyntic gland adenoma (OGA), gastric adenocarcinoma of the fundic-gland type (GA-FG), and gastric adenocarcinoma of the fundic-gland mucosa type (GA-FGM). There is no consensus on the cause, classification, and clinicopathological features of GEN-FGMLs, and misdiagnosis is common because of similarities in symptoms.</p><p><strong>Methods: </strong>37 cases diagnosed with GEN-FGMLs were included in this study. H&E-stained slides were reviewed and clinicopathological parameters were recorded. Immunohistochemical staining was conducted for MUC2, MUC5AC, MUC6, CD10, CD56, synaptophysin, chromograninA, p53, Ki67, pepsinogen-I, H⁺/K⁺-ATPase and Desmin.</p><p><strong>Results: </strong>The patients' ages ranged from 42 to 79 years, with a median age of 60. 17 were male and 20 were female. Morphologically, 19 OGAs, 16 GA-FGs, and two GA-FGMs were identified. Histopathological similarities exist between OGA, GA-FG, and GA-FGM. The tumors demonstrated well-formed glands, expanding with dense growth patterns comprising pale, blue-grey columnar cells with mild nuclear atypia. These cells resembled fundic gland cells. None of the OGA invaded the submucosal layer. The normal gastric pit epithelium covered the entire surface of the OGA and GA-FG, but the dysplasia pit epithelium covered the GA-FGM. Non-atrophic gastritis was observed in more than half of the background mucosa. All cases were diffusely positive for MUC6 and pepsinogen-I on immunohistochemistry. H⁺/K⁺-ATPase staining was negative or showed a scattered pattern in most cases. MUC5AC was expressed on the surface of GA-FGMs. p53 was focally expressed and the Ki67 index was low (1%-20%). Compared with OGA, GA-FG and GA-FGM were more prominent in the macroscopic view (<i>p</i> < 0.05) and had larger sizes (<i>p</i> < 0.0001). Additionally, GA-FG and GA-FGM exhibited higher Ki67 indices than OGA (<i>p</i> < 0.0001). Specimens with Ki-67 proliferation indices >2.5% and size >4.5 mm are more likely to be diagnosed with GA-FG and GA-FGM than OGA.</p><p><strong>Conclusion: </strong>GEN-FGMLs are group of well-differentiated gastric tumors with favourable biological behaviours, low cellular atypia, and low proliferation. Immunohistochemistry is critical for confirming diagnosis. Compared with OGA, GA-FG and GA-FGM have larger sizes and higher Ki67 proliferation indices, indicating that they play a critical role in the identification of GEN-FGML. Pathologists and endoscopists should be cautious to prevent misdiagnosis and overtreatment, especially in biopsy specimens.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611734"},"PeriodicalIF":2.3,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11169639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141317873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: Case report: A rare case of tumor-to-tumor metastasis: metastatic lobular breast carcinoma to clear cell renal cell carcinoma.","authors":"","doi":"10.3389/pore.2024.1611784","DOIUrl":"https://doi.org/10.3389/pore.2024.1611784","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.3389/pore.2023.1611204.].</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611784"},"PeriodicalIF":2.8,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11027495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140852336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: MiR-184 retarded the proliferation, invasiveness and migration of glioblastoma cells by repressing stanniocalcin-2.","authors":"","doi":"10.3389/pore.2024.1611767","DOIUrl":"https://doi.org/10.3389/pore.2024.1611767","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1007/s12253-017-0298-z.].</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611767"},"PeriodicalIF":2.8,"publicationDate":"2024-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11007041/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140858458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary.","authors":"Peter Batar, Hussain Alizadeh, Gyorgy Rokszin, Zsolt Abonyi-Toth, Judit Demeter","doi":"10.3389/pore.2024.1611758","DOIUrl":"https://doi.org/10.3389/pore.2024.1611758","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/pore.2024.1611497.].</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611758"},"PeriodicalIF":2.8,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10991778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140874704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Positive correlation between persistence of medical nutrition therapy and overall survival in patients with head and neck cancer.","authors":"Andrea Molnár, Erzsébet Pálfi, Barbara Belák, Célia Blasszauer, Dániel Reibl, József Lövey","doi":"10.3389/pore.2024.1611664","DOIUrl":"10.3389/pore.2024.1611664","url":null,"abstract":"<p><p><b>Background:</b> Several factors can affect overall survival of head and neck cancer (HNC) patients, including characteristics of the cancer disease and response to treatments. However, patients' nutritional status and the effectiveness of medical nutrition therapy (MNT) can also impact overall survival. The primary goal of our research was to collect real-life data on the use of MNT in HNC patients and to specifically investigate the correlation between survival and the duration of uninterrupted (persistent) nutrition. <b>Method:</b> The data of this retrospective, analytical, cohort study was collected from electronic healthcare records from the Hungarian National Health Insurance Fund Management. Overall, 38,675 HNC patients' data of the period between 2012 and 2021 was used. We applied multi-step exclusions to identify patient groups accurately and to avoid biasing factors. Statistical analysis was done by the Kaplan-Meier method, log-rank test, and Cox regression analysis. <b>Results:</b> Throughout the investigated period 16,871 (64%) patients received MNT therapy out of 26,253 newly diagnosed patients (≥18 years). In terms of the persistence of MNT, we divided the patients into three groups (1-3; 4-6; ≥7-month duration of MNT). When comparing these groups, we found that patients receiving long-term (≥7 months) MNT had a significantly longer overall survival (<i>p</i> < 0.0001) than those who received MNT for a shorter duration, both in locally advanced and recurrent/metastatic cases. <b>Conclusion:</b> The main outcome of the study is that there is a positive correlation between the persistence of MNT and the overall survival in HNC patients when nutritional intervention lasts several months. It highlights the responsibility of the specialists during the patient journey to use MNT early and to continue its use for as long as it is beneficial to the patients.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611664"},"PeriodicalIF":2.8,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10979420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140336507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"mTOR hyperactivity and <i>RICTOR</i> amplification as targets for personalized treatments in malignancies.","authors":"Dániel Sztankovics, Dorottya Moldvai, Gábor Petővári, Titanilla Dankó, Fatime Szalai, Risa Miyaura, Viktória Varga, Noémi Nagy, Gergő Papp, Judit Pápay, Ildikó Krencz, Anna Sebestyén","doi":"10.3389/pore.2024.1611643","DOIUrl":"10.3389/pore.2024.1611643","url":null,"abstract":"<p><p>The increasing knowledge of molecular alterations in malignancies, including mutations and regulatory failures in the mTOR (mechanistic target of rapamycin) signaling pathway, highlights the importance of mTOR hyperactivity as a validated target in common and rare malignancies. This review summarises recent findings on the characterization and prognostic role of mTOR kinase complexes (mTORC1 and mTORC2) activity regarding differences in their function, structure, regulatory mechanisms, and inhibitor sensitivity. We have recently identified new tumor types with <i>RICTOR</i> (rapamycin-insensitive companion of mTOR) amplification and associated mTORC2 hyperactivity as useful potential targets for developing targeted therapies in lung cancer and other newly described malignancies. The activity of mTOR complexes is recommended to be assessed and considered in cancers before mTOR inhibitor therapy, as current first-generation mTOR inhibitors (rapamycin and analogs) can be ineffective in the presence of mTORC2 hyperactivity. We have introduced and proposed a marker panel to determine tissue characteristics of mTOR activity in biopsy specimens, patient materials, and cell lines. Ongoing phase trials of new inhibitors and combination therapies are promising in advanced-stage patients selected by genetic alterations, molecular markers, and/or protein expression changes in the mTOR signaling pathway. Hopefully, the summarized results, our findings, and the suggested characterization of mTOR activity will support therapeutic decisions.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611643"},"PeriodicalIF":2.8,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10954904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140185094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: High expression of long noncoding RNA HOTAIRM1 is associated with the proliferation and migration in pancreatic ductal adenocarcinoma.","authors":"","doi":"10.3389/pore.2024.1611728","DOIUrl":"https://doi.org/10.3389/pore.2024.1611728","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1007/s12253-018-00570-4.].</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611728"},"PeriodicalIF":2.3,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11268321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141760225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic body radiotherapy in lung cancer: a contemporary review.","authors":"Emese Csiki, Mihály Simon, Judit Papp, Márton Barabás, Johanna Mikáczó, Kristóf Gál, David Sipos, Árpád Kovács","doi":"10.3389/pore.2024.1611709","DOIUrl":"10.3389/pore.2024.1611709","url":null,"abstract":"<p><p>The treatment of early stage non-small cell lung cancer (NSCLC) has improved enormously in the last two decades. Although surgery is not the only choice, lobectomy is still the gold standard treatment type for operable patients. For inoperable patients stereotactic body radiotherapy (SBRT) should be offered, reaching very high local control and overall survival rates. With SBRT we can precisely irradiate small, well-defined lesions with high doses. To select the appropriate fractionation schedule it is important to determine the size, localization and extent of the lung tumor. The introduction of novel and further developed planning (contouring guidelines, diagnostic image application, planning systems) and delivery techniques (motion management, image guided radiotherapy) led to lower rates of side effects and more conformal target volume coverage. The purpose of this study is to summarize the current developments, randomised studies, guidelines about lung SBRT, with emphasis on the possibility of increasing local control and overall rates in \"fit,\" operable patients as well, so SBRT would be eligible in place of surgery.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611709"},"PeriodicalIF":2.8,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10928908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140111098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Geroscience and pathology: a new frontier in understanding age-related diseases.","authors":"Monika Fekete, David Major, Agnes Feher, Vince Fazekas-Pongor, Andrea Lehoczki","doi":"10.3389/pore.2024.1611623","DOIUrl":"10.3389/pore.2024.1611623","url":null,"abstract":"<p><p>Geroscience, a burgeoning discipline at the intersection of aging and disease, aims to unravel the intricate relationship between the aging process and pathogenesis of age-related diseases. This paper explores the pivotal role played by geroscience in reshaping our understanding of pathology, with a particular focus on age-related diseases. These diseases, spanning cardiovascular and cerebrovascular disorders, malignancies, and neurodegenerative conditions, significantly contribute to the morbidity and mortality of older individuals. We delve into the fundamental cellular and molecular mechanisms underpinning aging, including mitochondrial dysfunction and cellular senescence, and elucidate their profound implications for the pathogenesis of various age-related diseases. Emphasis is placed on the importance of assessing key biomarkers of aging and biological age within the realm of pathology. We also scrutinize the interplay between cellular senescence and cancer biology as a central area of focus, underscoring its paramount significance in contemporary pathological research. Moreover, we shed light on the integration of anti-aging interventions that target fundamental aging processes, such as senolytics, mitochondria-targeted treatments, and interventions that influence epigenetic regulation within the domain of pathology research. In conclusion, the integration of geroscience concepts into pathological research heralds a transformative paradigm shift in our understanding of disease pathogenesis and promises breakthroughs in disease prevention and treatment.</p>","PeriodicalId":19981,"journal":{"name":"Pathology & Oncology Research","volume":"30 ","pages":"1611623"},"PeriodicalIF":2.3,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10922957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}